by ecancer reporter Audrey Nailor
The public is bombarded with news of innovative developments in cancer research every day, with new anti-cancer drugs greeted with excitement.
But what happens to these drugs? When do they become accessible to cancer patients – if at all?
In a new review published in ecancermedicalscience, researchers trace the journey anti-cancer drugs take between discovery and clinical practice.
"Bringing a new medication to clinical practice is a lengthy process and involves many stakeholders with a very diverse background, ranging from researchers, regulatory agencies, payers, physicians and patients," says Dr Felipe Ades of the Jules Bordet Institute, lead author of the review.
Prior to being incorporated into daily practice, drugs must obtain regulatory approval, succeed in changing the prescription habits of physicians, and ultimately gain the compliance of individual patients.
Each stage of development presents unique hurdles and challenges – for example, the average time for a drug to gain approval in the European Union is 418 days.
Once an anti-cancer drug is launched in the market, it takes around 3 years to have maximum impact on survival.
The complex life history of anti-cancer ends in the hands of the patient – who may not be inclined to take the drug at all.
"Aligning these different interests and expertise is a challenging task, but certainly a "win-win-win-win" situation," Dr Ades says.
Reference
Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart M and Parent F (2014) Hurdles and delays in access to anti-cancer drugs in Europe ecancermedicalscience
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.